"studyTitle","studyAcronym","id","studyRationale","uuid:ID","studyVersion"
"Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","LZZT","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","0c8ea075-aeac-4803-898c-6bea7828b24a","2"
